Efficacy and Safety of a Dexamethasone Intracanalicular Inse
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to evaluate the efficacy and safety of a dexamethasone intracanalicular ocular insert for treatment of allergic conjunctivitis that inferred the potential to provide relief of ocular itching.

A modified variant of the Ora-CAC® (conjunctival allergen challenge) protocol was used to test subjects with allergic conjunctivitis who were randomized 1:1 to dexamethasone or placebo inserts in both eyes. A series of four closely spaced post-insertion CACs were performed over the course of about 30 days after in-office insert placement. Subject-reported ocular itching at 3, 5, and 7 minutes post-CAC, as well as investigator-evaluated conjunctival redness at 7, 15, and 20 minutes post-CAC, were the primary efficacy endpoints measured at Week 1 CAC Day 8.

--For the primary endpoints, dexamethasone insert showed statistically significantly lower mean ocular itch scores compared with placebo at all time points, with differences favoring dexamethasone insert over placebo (0.86, 0.98, and 0.96 units at 3, 5, and 7 minutes, respectively), and statistically significantly lower conjunctival redness scores at 20 minutes but not at 7 or 15 minutes.

--Results also showed statistically significantly less itching and conjunctival redness at 31 and 29 of 33 other time points, respectively.

--There were no serious AEs; one subject had elevated intraocular pressure in both eyes.

To summarize, the findings show that a single, physician-administered dexamethasone intracanalicular insert has the potential to provide relief of ocular itching for up to 4 weeks in subjects with allergic conjunctivitis while retaining a favorable safety profile.

Source: https://www.ajo.com/article/S0002-9394(21)00130-6/fulltext?rss=yes